Merkel cell polyomavirus (MCPyV) DNA prevalence in Brazilian blood donors

Autor(es):Mostrar menos -

Zucherato, Victoria Simionatto ; da Costa, Pericles Natan Mendes ; Giovanetti, Marta ; Krause, Luciana Maria Fontanari ; Alves, Daiani Cristina Ciliao ; Moreira, Renata Maria Alencar ; Pimentel, Barbara Maciel Sidou ; Haddad, Rodrigo ; Bitencourt, Hellen Tayana ; Ciccozzi, Massimo ; Junior Alcantara, Luiz Carlos ; Kashima, Simone ; Covas, Dimas Tadeu ; Slavov, Svetoslav Nanev

• Tipo de documento: Artigo Científico
• Fonte: TRANSFUSION CLINIQUE ET BIOLOGIQUE; v. 30, n. 1, p. 4-pg., 2023-01-31.

Resumo

Merkel cell polyomavirus (MCPyV) is an oncogenic virus that has been etiologically linked to Merkel cell carcinoma. Low levels of MCPyV DNA have been detected in blood donors with unclear impact on trans-fusion. The prevalence of MCPyV DNA in Brazilian blood donors is unclear. Therefore, the objective of this study was to evaluate the MCPyV DNA prevalence among Brazilian blood donors. We examined the pre-sence of MCPyV DNA by real-time PCR (qPCR) in a total of 450 serum samples obtained from blood donors from three Brazilian regions (North, Central-West and South). The overall estimated MCPyV DNA preva-lence was 1.1% (CI = 95%, 0.16-2.06%). Divided by region, in North Brazil (city of Macapa, state of Amapa) and South Brazil (city of Santa Maria, state of Rio Grande do Sul), the MCPyV prevalence was the same: 1.33% (CI = 95%, range 0.0-3.14%). In Central-West Brazil (city of Brasilia), the MCPyV prevalence was 0.6% (CI = 95%, 0.0-1.96%). All MCPyV positive samples showed a high cycle threshold (median Ct = 35.5), most probably related to the low viral load. More studies are necessary to unveil the impact of this oncogenic virus on transfusion medicine and if such exists, especially in regards of its infectivity and transmission potential. (c) 2022 Societe francaise de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved. (AU)

• Processo FAPESP: 20/13194-1 - Avaliação molecular da prevalência e aplicação de métodos de sequenciamento de última geração para identificação de vírus emergentes na área de hemoterapia
• Beneficiário: Victória Simionatto Zucherato
• Modalidade de apoio: Bolsas no Brasil - Programa Capacitação - Treinamento Técnico
• Processo FAPESP: 17/23205-8 - Avaliação do impacto de vírus emergentes e re-emergentes em hemoterapia e transplante de células-tronco por meio de técnicas moleculares avançadas
• Beneficiário: Svetoslav Nanev Slavov
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores
• Processo FAPESP: 18/15826-5 - Avaliação do impacto de vírus emergentes e re-emergentes em hemoterapia e transplante de células-tronco por meio de técnicas moleculares avançadas
• Beneficiário: Svetoslav Nanev Slavov
• Modalidade de apoio: Bolsas no Brasil - Jovens Pesquisadores